Damora Therapeutics, Inc. (DMRA)
NASDAQ: DMRA · Real-Time Price · USD
24.16
-0.83 (-3.32%)
May 8, 2026, 4:00 PM EDT - Market closed
Company Description
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America.
The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia.
Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Damora Therapeutics, Inc.
| Country | United States |
| Founded | 2011 |
| IPO Date | Oct 29, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Jennifer Jarrett |
Contact Details
Address: Building 23, Suite 105 Waltham, Massachusetts 02453 United States | |
| Phone | 781 281 9020 |
| Website | damoratx.com |
Stock Details
| Ticker Symbol | DMRA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1800315 |
| ISIN Number | US36322Q2066 |
| Employer ID | 37-1957007 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jennifer A. Jarrett M.B.A. | Chief Executive Officer, President and Director |
| Lori C. Firmani | Chief Financial Officer |
| Garrett Winslow Esq. | Senior Vice President, General Counsel and Corporate Secretary |
| Ulf J. Nilsson Ph.D. | Co-Founder |
| Dr. Hakon Leffler M.D., Ph.D. | Co-Founder |
| Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D. | Co-Founder |
| Sherwin Sattarzadeh | Chief Operating Officer |
| Dr. Becker Hewes M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 4, 2026 | 8-K | Current Report |
| May 1, 2026 | ARS | Filing |
| Apr 29, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 29, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2026 | SCHEDULE 13G/A | Filing |
| Apr 23, 2026 | SCHEDULE 13G/A | Filing |
| Apr 20, 2026 | 8-K | Current Report |
| Mar 23, 2026 | 8-K | Current Report |
| Mar 20, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 19, 2026 | 10-K | Annual Report |